SAGE
Price:
$5.73
Market Cap:
$350.52M
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases...[Read more]
Industry
Biotechnology
IPO Date
2014-07-18
Stock Exchange
NASDAQ
Ticker
SAGE
According to Sage Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.03. This represents a change of -72.93% compared to the average of -3.80 of the last 4 quarters.
The mean historical PE Ratio of Sage Therapeutics, Inc. over the last ten years is -9.70. The current -1.03 PE Ratio has changed 962.18% with respect to the historical average. Over the past ten years (40 quarters), SAGE's PE Ratio was at its highest in in the December 2020 quarter at 1.16. The PE Ratio was at its lowest in in the June 2018 quarter at -107.27.
Average
-9.70
Median
-8.20
Minimum
-23.35
Maximum
7.42
Discovering the peaks and valleys of Sage Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 116.12%
Maximum Annual PE Ratio = 7.42
Minimum Annual Increase = -231.46%
Minimum Annual PE Ratio = -23.35
Year | PE Ratio | Change |
---|---|---|
2023 | -2.39 | -46.72% |
2022 | -4.49 | -18.81% |
2021 | -5.54 | -174.61% |
2020 | 7.42 | -231.46% |
2019 | -5.64 | -52.36% |
2018 | -11.85 | -49.00% |
2017 | -23.23 | 116.12% |
2016 | -10.75 | -37.28% |
2015 | -17.14 | -26.62% |
2014 | -23.35 | -15.44% |
The current PE Ratio of Sage Therapeutics, Inc. (SAGE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.14
5-year avg
-2.13
10-year avg
-9.70
Sage Therapeutics, Inc.’s PE Ratio is greater than Apellis Pharmaceuticals, Inc. (-14.50), greater than Terns Pharmaceuticals, Inc. (-5.57), greater than Day One Biopharmaceuticals, Inc. (-18.08), greater than Blueprint Medicines Corporation (-47.82), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Mirati Therapeutics, Inc. (-5.32), greater than Amylyx Pharmaceuticals, Inc. (-1.64), greater than Relay Therapeutics, Inc. (-2.41), greater than Stoke Therapeutics, Inc. (-7.28), greater than Pliant Therapeutics, Inc. (-4.16), greater than Black Diamond Therapeutics, Inc. (-2.50), greater than Arvinas, Inc. (-6.15), less than Krystal Biotech, Inc. (102.65), greater than Alnylam Pharmaceuticals, Inc. (-104.09), greater than Madrigal Pharmaceuticals, Inc. (-14.21), less than Incyte Corporation (477.87), greater than Reata Pharmaceuticals, Inc. (-89.36), greater than DiaMedica Therapeutics Inc. (-8.24), greater than Akero Therapeutics, Inc. (-9.48), greater than Nuvalent, Inc. (-33.86), greater than Immunocore Holdings plc (-31.42), less than Ventyx Biosciences, Inc. (-0.97),
Company | PE Ratio | Market cap |
---|---|---|
-14.50 | $3.64B | |
-5.57 | $605.41M | |
-18.08 | $1.58B | |
-47.82 | $6.14B | |
-17.73 | $8.19B | |
-5.32 | $4.12B | |
-1.64 | $424.83M | |
-2.41 | $994.26M | |
-7.28 | $721.41M | |
-4.16 | $841.00M | |
-2.50 | $183.34M | |
-6.15 | $1.81B | |
102.65 | $5.38B | |
-104.09 | $34.69B | |
-14.21 | $7.39B | |
477.87 | $15.52B | |
-89.36 | $6.57B | |
-8.24 | $184.24M | |
-9.48 | $2.25B | |
-33.86 | $6.35B | |
-31.42 | $1.69B | |
-0.97 | $148.41M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sage Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Sage Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Sage Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Sage Therapeutics, Inc. (SAGE)?
What is the highest PE Ratio for Sage Therapeutics, Inc. (SAGE)?
What is the 3-year average PE Ratio for Sage Therapeutics, Inc. (SAGE)?
What is the 5-year average PE Ratio for Sage Therapeutics, Inc. (SAGE)?
How does the current PE Ratio for Sage Therapeutics, Inc. (SAGE) compare to its historical average?